In a study published this month in the Journal of Clinical Oncology, the results of a clinical trial of the drug bevacizumab to treat colon cancer in combination with the standard therapy found that the drug did not significantly increase disease-free survival in patients with stage II and stage III colon cancer.
Cell signaling protein may hold key to blocking long-studied genetic mutation
$11.9 Million in awards to address cancer disparities
N.C. native John Isner and doubles partner Sam Querrey to host
ABC Anchor Robin Roberts Guest of Honor at Kickoff Event
Project Focuses on Efficient, Low-Cost Genetic Analysis
UNC Scientists Receive Grant to Develop Nanotechnology for Pancreatic Cancer Diagnosis and Treatment
National Cancer Institute awards $13.6 million to UNC's Carolina Center of Cancer Nanotechnology Excellence
The article "How Old Are You, Really?" written by Mark Derewicz and published in the Fall 2010 issue of Endeavors magazine features UNC Lineberger member Ned Sharpless, MD. Dr. Sharpless is an associate professor of medicine and genetics and associate director for translational research at UNC Lineberger.
Part of UNC Comprehensive Cancer Support Program